Recruiting

Pregabalin and Lacosamide for Post-Herpetic Neuralgia in Herpes Zoster Patients

0 criteria met from your profileSee at a glance how your profile meets each eligibility criteria.
What is being tested

Pregabalin

+ Lacosamide

Drug
Who is being recruted

Varicella Zoster Virus Infection+12

+ DNA Virus Infections

+ Herpes Zoster

From 18 to 50 Years
+6 Eligibility Criteria
See all eligibility criteria
How is the trial designed

Treatment Study

Interventional
Study Start: April 2025
See protocol details

Summary

Principal SponsorCMH Kharian Medical College
Study ContactMushayada Irshad, MBBS, MPhil PharmacologyMore contacts
Last updated: January 28, 2026
Sourced from a government-validated database.Claim as a partner

Study start date: April 10, 2025

Actual date on which the first participant was enrolled.

Post-herpetic neuralgia (PHN) is a painful condition that arises after shingles, a viral infection caused by the reactivation of the chickenpox virus. This pain can last long after the rash clears up and is particularly burdensome for older adults and those with weakened immune systems. It can disrupt sleep and daily activities due to its chronic and sometimes severe nature. This study focuses on comparing two medications, Pregabalin and Lacosamide, both known to alleviate neuropathic pain, to determine which is more effective in treating PHN. The insights gained could help improve treatment choices for those suffering from this challenging condition. Participants in the study receive either Pregabalin or Lacosamide to manage their PHN symptoms. The study evaluates how well each medication reduces pain and improves the quality of life for patients. By comparing these two treatments, researchers hope to identify the most effective option, helping doctors make informed decisions about managing PHN. The study does not specify any particular risks or benefits, focusing instead on understanding the relative effectiveness of the two drugs.

Official TitleComparative Efficacy of Pregabalin and Lacosamide in Patients With Herpes Zoster and Post Herpetic Neuralgia
NCT06969417
Principal SponsorCMH Kharian Medical College
Study ContactMushayada Irshad, MBBS, MPhil PharmacologyMore contacts
Last updated: January 28, 2026
Sourced from a government-validated database.Claim as a partner

Protocol

This section provides details of the study plan, including how the study is designed and what the study is measuring.
Design Details

50 patients to be enrolled

Total number of participants that the clinical trial aims to recruit.

Treatment Study

These studies test new ways to treat a disease, condition, or health issue. The goal is to see if a new drug, therapy, or approach works better or has fewer side effects than existing options.



Eligibility

Researchers look for people who fit a certain description, called eligibility criteria: person's general health condition or prior treatments.
Conditions
Criteria

Any sex

Biological sex of participants that are eligible to enroll.

From 18 to 50 Years

Range of ages for which participants are eligible to join.

Healthy volunteers not allowed

If individuals who are healthy and do not have the condition being studied can participate.

Conditions

Pathology

Varicella Zoster Virus InfectionDNA Virus InfectionsHerpes ZosterHerpesviridae InfectionsInfectionsNervous System DiseasesNeuralgiaNeurologic ManifestationsNeuromuscular DiseasesPainPeripheral Nervous System DiseasesSigns and SymptomsPathological Conditions, Signs and SymptomsVirus DiseasesNeuralgia, Postherpetic

Criteria

3 inclusion criteria required to participate
Diagnosed cases of herpes zoster suffering from postherpetic neuralgia

Ages: 18 to 50

Both male and female

3 exclusion criteria prevent from participating
Lack of consent

Patient already taking pain killers for post herpetic neuralgia

Patients suffering from other systemic illness

Study Plan

Find out more about all the medication administered in this study, their detailed description and what they involve.
Treatment Groups
Study Objectives

2 intervention groups are designated in this study

This study does not include a placebo group 

Treatment Groups

Group I

Active Comparator
Group A will receive Cap Pregabalin, the first intervention

Group II

Experimental
Group B will receive Tab Lacosamide

Study Objectives

Primary Objectives

Study Centers

These are the hospitals, clinics, or research facilities where the trial is being conducted. You can find the location closest to you and its status.

This study has 1 location

Recruiting

CMH Kharian Medical College

Kharan, PakistanOpen CMH Kharian Medical College in Google Maps
Recruiting
One Study Center
Pregabalin and Lacosamide for Post-Herpetic Neuralgia in Herpes Zoster Patients | PatLynk